Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Kimball

Showing results (181-190 of 230) with videos related to

Pageof 23
Sort By:
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
The British Journal of Dermatology|September 16, 2023
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeJames G Krueger, John Frew, Gregor B E Jemec, et al.
Dermatology and Therapy|December 30, 2022
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims DataAmit Garg, Haley B Naik, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.
Experimental Dermatology|May 31, 2022
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept studyAlexa B Kimball, Christian Loesche, Errol P Prens, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Dermatology (Basel, Switzerland)|November 5, 2024
Treatment Satisfaction in Patients with Hidradenitis Suppurativa: A Real-World Survey from the EU5 and USAJohn R Ingram, Vincenzo Bettoli, Jasmine I Espy, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Pageof 23

Showing results (181-190 of 230) with videos related to

Sort By:
Pageof 23
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
The British Journal of Dermatology|September 16, 2023
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeJames G Krueger, John Frew, Gregor B E Jemec, et al.
Dermatology and Therapy|December 30, 2022
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims DataAmit Garg, Haley B Naik, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.
Experimental Dermatology|May 31, 2022
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept studyAlexa B Kimball, Christian Loesche, Errol P Prens, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Dermatology (Basel, Switzerland)|November 5, 2024
Treatment Satisfaction in Patients with Hidradenitis Suppurativa: A Real-World Survey from the EU5 and USAJohn R Ingram, Vincenzo Bettoli, Jasmine I Espy, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Pageof 23